ReviewReviews in cardiovascular medicine2026
Chronic Thromboembolic Pulmonary Hypertension as an Inflammation-Angiogenesis Disorder: From Thrombus Persistence to Dual Pulmonary Vasculopathy.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious but potentially treatable complication of acute pulmonary embolism. CTEPH is characterized by persistent obstruction of the pulmonary arteries and elevated pulmonary pressure. Although organized blood clots have long been considered the primary cause, recent research indicates that CTEPH is more complex. Indeed, CTEPH encompasses ongoing endothelial dysfunction and dysregulated angiogenic recanalization within organized thrombi. Unlike previous reviews that address these pathways in isolation, this review integrates inflammation and angiogenesis into a unified mechanistic framework, incorporating recent single-cell transcriptomic data and epigenetic findings to outline the development and progression of CTEPH. The review also examines both established and emerging pathomechanisms of CTEPH, focusing on how local blood flow and endothelial activation shape the disease. Moreover, this review highlights the concept of dual vasculopathy, encompassing both significant vessel occlusions and small-vessel changes, similar to those observed in pulmonary arterial hypertension. Additionally, the review examines the role of inflammation in CTEPH, including the involvement of neutrophils, neutrophil extracellular traps, high-mobility group box 1 protein, monocytes, macrophages, and adaptive immune responses, as revealed by single-cell analyses. This review further discusses how endothelial dysfunction is linked to inflammation, thrombosis, and remodeling of the pulmonary vasculature. Particular attention is provided to abnormal von Willebrand factor levels,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.